PREDNISOLONE SODIUM PHOSPHATE ORAL SOLUTION- prednisolone sodium phosphate solution 미국 - 영어 - NLM (National Library of Medicine)

prednisolone sodium phosphate oral solution- prednisolone sodium phosphate solution

mission pharmacal company - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 25 mg in 5 ml - prednisolone sodium phosphate oral solution (25 mg prednisolone per 5 ml) is indicated in the following conditions: 1. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. dermatologic diseases pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. edematous states to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephritic syndrome, without uremia. 4. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; i

PREDNISOLONE SODIUM PHOSPHATE solution 미국 - 영어 - NLM (National Library of Medicine)

prednisolone sodium phosphate solution

a-s medication solutions - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution is indicated in the following conditions: - allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. - dermatologic diseases: pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. - edematous states: to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. - endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocort

PREDNISOLONE SODIUM PHOSPHATE solution 미국 - 영어 - NLM (National Library of Medicine)

prednisolone sodium phosphate solution

carilion materials management - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution (15 mg prednisolone per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital ad

PREDNISOLONE SODIUM PHOSPHATE solution 미국 - 영어 - NLM (National Library of Medicine)

prednisolone sodium phosphate solution

burke therapeutics - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone sodium phosphate oral solution (20 mg prednisolone base per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenit

Betnesol 0.1% w/v Eye, Ear and Nasal Drops, solution 아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

betnesol 0.1% w/v eye, ear and nasal drops, solution

rph pharmaceuticals ab - betamethasone sodium phosphate - ear/eye/nasal drops, solution - 0.1 percent weight/volume - corticosteroids; betamethasone

Betnesol 500 microgram Soluble Tablets 아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

betnesol 500 microgram soluble tablets

rph pharmaceuticals ab - betamethasone sodium phosphate - soluble tablet - 500 microgram(s) - glucocorticoids; betamethasone

Diprophos Disposable Syringe 5 mg/ml - 2 mg/ml inj. susp. p.artic./i.laes./i.artic./i.burs./i.m. pre-filled syr. 벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

diprophos disposable syringe 5 mg/ml - 2 mg/ml inj. susp. p.artic./i.laes./i.artic./i.burs./i.m. pre-filled syr.

organon belgium bv-srl - betamethasone sodium phosphate 2,63 mg/ml - eq. betamethasone 2 mg/ml; betamethasone dipropionate 6,43 mg/ml - eq. betamethasone 5 mg/ml - suspension for injection - 5 mg/ml - 2 mg/ml - betamethasone sodium phosphate 2.63 mg/ml; betamethasone dipropionate 6.43 mg/ml - betamethasone

Diprophos Disposable Syringe 10 mg/2 ml - 4 mg/2 ml inj. susp. p.artic./i.laes./i.artic./i.burs./i.m. pre-filled syr. 벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

diprophos disposable syringe 10 mg/2 ml - 4 mg/2 ml inj. susp. p.artic./i.laes./i.artic./i.burs./i.m. pre-filled syr.

organon belgium bv-srl - betamethasone sodium phosphate 2,63 mg/ml - eq. betamethasone 2 mg/ml; betamethasone dipropionate 6,43 mg/ml - eq. betamethasone 5 mg/ml - suspension for injection - 5 mg/ml - 2 mg/ml - betamethasone sodium phosphate 2.63 mg/ml; betamethasone dipropionate 6.43 mg/ml - betamethasone

Celestone 4 mg/ml inj. sol. i.laes./i.v./i.artic./i.burs./i.m. amp. 벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

celestone 4 mg/ml inj. sol. i.laes./i.v./i.artic./i.burs./i.m. amp.

organon belgium bv-srl - betamethasone sodium phosphate 5,3 mg - eq. betamethasone 4 mg/ml - solution for injection - 4 mg/ml - betamethasone sodium phosphate 5.3 mg - betamethasone

LAEOVATE N DROPS Ear/Eye Drops, Solution 케냐 - 영어 - Pharmacy and Poisons Board

laeovate n drops ear/eye drops, solution

laboratory & allied ltd p.o box 42875 gpo 00100 nairobi, kenya - betamethasone sodium phosphate neomycin sulphate… - ear/eye drops, solution - betamethasone sodium phosphate bp 0.1 % w/v … - otological anti-infectives